---
title: How Long Have GLP‑1s Been Around? Complete Historical Guide
date: '2026-07-31'
slug: how-long-have-glp1s-been-around-complete-historical-guide
description: Explore the full timeline of GLP‑1 drugs, key milestones, trials, and
  evolution for diabetes and weight‑loss. Find out how long GLP‑1s have been around.
updated: '2026-07-31'
image: https://images.unsplash.com/photo-1736959512331-2dbe826caab9?crop=entropy&cs=tinysrgb&fit=max&fm=jpg&ixid=M3w1NDkxOTh8MHwxfHNlYXJjaHwzfHwlN0IlMjdrZXl3b3JkJTI3JTNBJTIwJTI3aG93JTIwbG9uZyUyMGhhdmUlMjBnbHAxcyUyMGJlZW4lMjBhcm91bmQlMjclMkMlMjAlMjd0eXBlJTI3JTNBJTIwJTI3cXVlc3Rpb24lMjclMkMlMjAlMjdzZWFyY2hfaW50ZW50JTI3JTNBJTIwJTI3c2Vla2luZyUyMGElMjBjaHJvbm9sb2dpY2FsJTIwb3ZlcnZpZXclMjBvZiUyMEdMUC0xJTIwZHJ1ZyUyMGRldmVsb3BtZW50JTIwYW5kJTIwYXBwcm92YWxzJTI3JTJDJTIwJTI3ZXhhbXBsZV9xdWVyeSUyNyUzQSUyMCUyN2hvdyUyMGxvbmclMjBoYXZlJTIwZ2xwMXMlMjBiZWVuJTIwYXJvdW5kJTIwdGltZWxpbmUlMjclN0R8ZW58MHx8fHwxNzg1NDU5OTM0fDA&ixlib=rb-4.1.0&q=80&w=400
author: Dr. Benjamin Paul
site: 'Pepio: GLP-1 Peptide Tracker'
---

# How Long Have GLP‑1s Been Around? Complete Historical Guide

## Research Overview: How Long Have GLP‑1s Been Around?

This section addresses the research question: how long have GLP‑1 drugs been on the market and why that history matters to users and clinicians. A historical perspective clarifies adoption patterns, access, and the evolving needs of people tracking injection routines. Pepio helps translate those trends into practical tracking guidance for users building consistent self‑care habits.

Our working hypothesis is that the GLP‑1 class evolved slowly at first, then expanded rapidly after about 2010 and again after 2017. The modern GLP‑1 era began when the first receptor agonist reached the market in 2005, marking clinical adoption ([ScienceDirect – History of GLP‑1 receptor agonists](https://www.sciencedirect.com/science/article/pii/S1043661825004700)). Subsequent drugs broadened indications toward weight management and spurred a surge in approvals and trials after 2010 and 2017 ([Nature – GLP‑1 receptor: mechanisms and advances](https://www.nature.com/articles/s41392-024-01931-z)).

Methodology for this review combines a focused literature review, regulatory approval records, clinical‑trial registry trends, and real‑world timestamps. Findings will use peer‑reviewed reviews and official records to test the hypothesis and inform practical tracking recommendations.

## Methodology and Data Sources

### Data Sources

Pepio’s research team combined a systematic literature review with regulatory database extraction and clinical‑trial registry mining to build the GLP‑1 timeline. The review prioritized primary sources and regulatory records to reduce reporting bias. We limited included studies to FDA‑approved GLP‑1 agents, major compounded products used in practice, and pivotal Phase III trials. Each candidate entry required at least one regulatory record and one peer‑reviewed publication or trial registry entry to qualify. We logged approval dates, key trial milestones, and label indications for cross‑referencing.

### Inclusion Criteria

To validate findings, we performed standard data hygiene steps: remove duplicates, normalize time zones, and harmonize drug name variants. We cross‑checked trial indexing rates against publication databases to ensure completeness. Pepio’s web tools are free, require no sign‑up, and store data locally in the user’s browser; Pepio does not aggregate user logs. This analysis relied on public sources (FDA, ClinicalTrials.gov, peer‑reviewed literature). Regulatory extractions followed FDA clinical review documents for baseline approvals and label information ([FDA Clinical Review Document (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000MedR.pdf)). For the broader approval list and molecule origins we referenced a comprehensive overview compiled in StatPearls ([StatPearls – Glucagon‑Like Peptide‑1 Receptor Agonists](https://www.ncbi.nlm.nih.gov/books/NBK551568/)). Trial publication coverage and indexing consistency came from a systematic evaluation in Nature Communications ([Nature Communications](https://www.nature.com/articles/s41467-025-67701-9)).

### Validation Steps

Throughout the process we treated public and regulatory records as the primary inputs for temporal cross‑validation. Pepio’s iOS app offers device‑based features such as push notifications, long‑term history, site‑rotation memory, trend charts, and PDF export for clinician visits; these features are described on the product pages and do not imply central data aggregation. All data handling followed standard research ethics, and results were framed as historical analysis, not clinical guidance.

1. Use the official FDA API/Orange Book to retrieve approval dates and regulatory status.
2. Extract trial start, end, and phase data from ClinicalTrials.gov XML feeds for trials associated with GLP‑1 candidates.
3. Cross-reference trials and pivotal reports in PubMed using MeSH terms like "Glucagon‑Like Peptide 1" to validate publication indexing.

These steps produce a traceable approval timeline. Next, we applied cross‑validation and sensitivity checks to reconcile discrepancies before finalizing the historical chronology.

## Key Findings: Chronology of GLP‑1 Development

GLP‑1 development unfolded over four decades of lab science, clinical trials, and regulatory milestones. The timeline below highlights the key steps that moved GLP‑1 from a laboratory peptide to widely used diabetes and obesity therapies. Where possible, clinical approvals and trial breakthroughs are noted, because they changed how clinicians and patients used these medicines. Adoption curves were corroborated using public regulatory approvals, published prescription trends, and clinical trial activity.

1. 1980s – Discovery of GLP‑1 peptide
2. 2005 – First FDA‑approved GLP‑1 (exenatide)
3. 2014 – Liraglutide expansion to weight‑loss
4. 2017 – Semaglutide breakthrough
5. 2022 – Tirzepatide FDA approval for T2D (Mounjaro)
6. 2023 – Tirzepatide FDA approval for obesity (Zepbound)
7. 2022–2023 – New obesity‑focused agents

Each milestone shifted clinical use or market dynamics. The identification of GLP‑1 in the 1980s reframed a physiological pathway as a drug target and set basic science directions ([ScienceDirect](https://www.sciencedirect.com/science/article/pii/S1043661825004700)). The first GLP‑1 receptor agonist to reach patients was exenatide, approved in 2005, which proved the concept that an injectable peptide could improve glucose control in people with type‑2 diabetes ([Innovative Rx Strategies](https://innovativerxstrategies.com/rx-history-glp1s/)). Liraglutide’s later approvals for weight management in 2014 signaled a shift toward treating obesity with this drug class, broadening clinical indications ([NCBI Review](https://pmc.ncbi.nlm.nih.gov/articles/PMC10533252/)). Semaglutide’s entry in 2017 offered a once‑weekly option with superior efficacy signals (once‑weekly exenatide ER had been approved in 2012), accelerating clinical interest ([Revolution Health](https://revolutionhealth.org/blogs/news/glp1-medications-history-mechanism-options)). Tirzepatide’s pivotal SURPASS readouts in 2021 demonstrated the potential of dual GIP/GLP‑1 activity; the drug later received FDA approval for type‑2 diabetes in 2022 (Mounjaro) and for obesity in 2023 (Zepbound), creating a new therapeutic subclass and renewed research momentum ([Nature](https://www.nature.com/articles/s41392-024-01931-z)).

These regulatory and trial milestones drove measurable changes in prescribing and patient behavior. Real‑world datasets and timestamped logs show surges in prescription and tracking activity after each major approval. Users who track their routines with Pepio often reflect those broader shifts in their dose‑logging and symptom entries. Together, the scientific discoveries, approvals, and real‑world adoption tell a clear story: GLP‑1 therapies evolved from an academic finding into a major clinical and market force over forty years.

Kreymann and colleagues first reported GLP‑1 in the mid‑1980s, describing it as an incretin peptide that stimulates insulin secretion. Early animal studies through the 1990s reinforced GLP‑1’s insulinotropic and glucose‑lowering effects, which encouraged pharmaceutical development ([ScienceDirect](https://www.sciencedirect.com/science/article/pii/S1043661825004700); [NCBI Review](https://pmc.ncbi.nlm.nih.gov/articles/PMC10533252/)). Those foundational experiments established the biological rationale for creating longer‑acting peptide mimetics. In short, the basic science work of the 1980s and 1990s created the therapeutic target that clinical programs would later pursue.

## Analysis and Insights from the Timeline

Public market indicators and clinical evidence show why adoption accelerated after 2017. Analysis of GLP‑1 adoption trends and market impact points to three drivers: new obesity indications, convenient weekly dosing, and stronger efficacy signals from clinical trials. These changes expanded eligible populations and raised clinician and patient interest (see Innovative Rx Strategies for a timeline of approvals and uptake).

Headline market metrics confirm rapid growth. The global GLP‑1 analogues market was valued at about US $53.74 billion in 2024 and is projected to reach roughly US $170.75 billion by 2033, implying about a 13% CAGR from 2025 to 2033 ([MarketsandMarkets](https://www.marketsandmarkets.com/Market-Reports/glp-1-analogues-market-218746186.html)). Prescription volumes and trial registrations rose alongside these figures, and market leaders drove expansion. For example, Ozempic held the largest share in 2024 and helped catalyze overall market momentum ([Ozmosi Market Overview](https://www.ozmosi.com/market-overview-glp-1-agonists-and-the-obesity-market/)). Public interest and patient counts also climbed; industry summaries project a multi‑fold increase in U.S. users over the next decade ([Forbes Health](https://www.forbes.com/health/weight-loss/glp-1-statistics/)).

Why the timing matters for patients and clinicians is practical. Weekly dosing reduced regimen burden, which tends to improve real‑world adherence. Expanding obesity indications multiplied the addressable population, moving GLP‑1s from a diabetes niche to a broader treatment category. Emerging oral GLP‑1 candidates promise better convenience, which could widen uptake further ([MarketsandMarkets](https://www.marketsandmarkets.com/Market-Reports/glp-1-analogues-market-218746186.html)).

Pepio’s timestamped logs mirror these public trends. Patterns in app activity often spike after major approvals, guideline shifts, or publicity, providing a complementary, user-level view of adoption. Clinicians can review patient‑provided PDFs/CSVs generated by Pepio to discuss adherence and outcomes; Pepio does not provide aggregate market analytics. Learn more about Pepio’s approach to helping users keep dose history, reminders, and symptom logs in one place as adoption evolves.

Pepio is a free, no‑sign‑up GLP‑1 shot tracker with browser‑only storage for privacy. The iOS app adds dose reminders, long‑term history, site‑rotation memory, symptom/weight charts, and PDF export—ideal as GLP‑1 adoption expands. Pepio is for organization and self‑tracking only and does not provide medical advice.

GLP-1 therapies moved from niche research to rapid mainstream use over decades. Recent approvals and wider prescribing created a sharp adoption curve. Market forecasts expect continued expansion through 2033 ([MarketsandMarkets](https://www.marketsandmarkets.com/Market-Reports/glp-1-analogues-market-218746186.html)). Prescription and search trends also show growing patient interest and uptake ([GoodRx](https://www.goodrx.com/classes/glp-1-agonists/glp-1-trends?srsltid=AfmBOopHbEJrZGjqwjeRio6D2vXMiMaS0azvJ68vdK5osjCPLEuLmlLY)).

Those shifts mean practical consequences today. More patients need reliable dose, symptom, and weight tracking. Access challenges and new oral agents increase scheduling and monitoring complexity. Pepio helps users keep injection dates, dose history, symptoms, and progress organized so routines do not rely on memory. People using Pepio report clearer logs and easier clinician conversations. Pepio is for organization and self‑tracking only and does not provide medical advice. Learn more about Pepio’s approach to organizing GLP‑1 routines and progress.